PT  - JOURNAL ARTICLE
AU  - Marc C. Shamier
AU  - Alma Tostmann
AU  - Susanne Bogers
AU  - Janet de Wilde
AU  - Jeroen IJpelaar
AU  - Willemijn A. van der Kleij
AU  - Herbert de Jager
AU  - Bart L. Haagmans
AU  - Richard Molenkamp
AU  - Bas. B. Oude Munnink
AU  - Carsten van Rossum
AU  - Janette Rahamat-Langendoen
AU  - Nannet van der Geest
AU  - Chantal P. Bleeker-Rovers
AU  - Heiman Wertheim
AU  - Marion P.G. Koopmans
AU  - Corine H. GeurtsvanKessel
TI  - Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
AID  - 10.1101/2021.08.20.21262158
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.20.21262158
4099  - http://medrxiv.org/content/early/2021/08/21/2021.08.20.21262158.short
4100  - http://medrxiv.org/content/early/2021/08/21/2021.08.20.21262158.full
AB  - Background SARS-CoV-2 vaccines are highly effective at preventing COVID-19-related morbidity and mortality. As no vaccine is 100% effective, breakthrough infections are expected to occur.Methods We analyzed the virological characteristics of 161 vaccine breakthrough infections in a population of 24,706 vaccinated healthcare workers (HCWs), using RT-PCR and virus culture.Results The delta variant (B.1.617.2) was identified in the majority of cases. Despite similar Ct-values, we demonstrate lower probability of infectious virus detection in respiratory samples of vaccinated HCWs with breakthrough infections compared to unvaccinated HCWs with primary SARS-CoV-2 infections. Nevertheless, infectious virus was found in 68.6% of breakthrough infections and Ct-values decreased throughout the first 3 days of illness.Conclusions We conclude that rare vaccine breakthrough infections occur, but infectious virus shedding is reduced in these cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Radboud university medical center Committee on Research Involving Human Subjects (CMO) and the Erasmus Medical Center Medical Ethics Committee (METC). All samples were collected following routine institutional COVID-19 testing guidelines, the participants were not subject to any procedures for the purpose of this study and all data were anonymized prior to analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request